Alastair Mcewan
Executive Vice President
Management
veloxis pharmaceuticals
Denmark
Biography
McEwan has had broad experience from financial, M & A and general management roles and board appointments in private and public companies. Before Veloxis he had a number of roles within Cornerstone Therapeutics (NASDAQ - CRTX) between 2005 and 2014. He is a past chairman of the board of Cornerstone and was its executive CFO during the acquisition and integration of EKR and the subsequent sale of the expanded Cornerstone to Chiesi in 2014. During the years between 2006 and 2009 he advised private equity firms in most of the larger CRO transactions following from his experience derived from Inveresk Research (NASDAQ - IRGI) and Averion International (NASDAQ – AVRO). At Inveresk he was a member of its Group Executive Board and President of its Global Clinical division. He was directly responsible for the acquisition and turn- around of the ClinTrials group (NASDAQ – CCRO) and instrumental in the subsequent sale of the enlarged Inveresk Group to Charles River Laboratories in 2004 (NYSE – CRL). At Averion he was a board member, interim CEO and chairman of its executive committee He is a Bachelor of Commerce from the University of Edinburgh and a Chartered Accountant.
Research Interest
M & A and general management
